Advertisement

Topics

Nippon Chemiphar Co., Ltd. And SOM Biotech To Cooperate On New, Orphan Disease Indications For Bevantolol (Calvan)

20:00 EDT 10 Oct 2017 | BioSpace

BARCELONA, Spain, October 11, 2017 /PRNewswire/ --SOM Biotech (SOM), a leading drug repurposing company based in Barcelona, Spain, has determined and validated an entirely new usage for Nippon Chemiphar's marketed hypertension therapy bevantolol (Calvan). SOM, after using a proprietary ligand analysis computational algorithm and completing the preclinical assays,...

Original Article: Nippon Chemiphar Co., Ltd. And SOM Biotech To Cooperate On New, Orphan Disease Indications For Bevantolol (Calvan)

NEXT ARTICLE

More From BioPortfolio on "Nippon Chemiphar Co., Ltd. And SOM Biotech To Cooperate On New, Orphan Disease Indications For Bevantolol (Calvan)"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pulmonary Hypertension
Pulmonary arterial hypertension (PAH) is a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs of affected individuals. Symptoms can range from mild breathles...